+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "LANCL2"

LanC Like Protein 2 - Pipeline Review, H2 2019 - Product Thumbnail Image

LanC Like Protein 2 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 37 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The LANCL2 market is a subset of the larger lung cancer drug market. It is focused on drugs that target the Langerhans cell histiocytosis (LCH) subtype of lung cancer. This type of cancer is rare and is characterized by the presence of Langerhans cells in the lungs. The drugs in this market are designed to target these cells and reduce the growth of the cancer. The drugs in the LANCL2 market are typically used in combination with other treatments, such as chemotherapy and radiation therapy. They are also used to reduce the risk of recurrence and improve the overall prognosis of the patient. The companies in the LANCL2 market include AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. These companies are all involved in the development and marketing of drugs for the treatment of LCH. Show Less Read more